The World Health Organisation defines Health as a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. Health exists thus not only into free from illness, but also refers the well-being of individual humans.
Acid-related conditions of the upper gastrointestinal tract, including gastroesophageal reflux disease (GERD) and peptic ulceration, can lead to severe symptoms with a major impact on quality of life. They are a major cause of poor health, especially in western countries, and patients are at risk of serious complications such as perforation or stricture, internal bleeding, and possible malignancy.
Treating gastrointestinal diseases
Nycomed is the manufacturer of pantoprazole, one of a class of drugs called proton pump inhibitors (PPIs), which reduce the secretion of acid in the stomach. They are widely recognized as the most effective agents available for the treatment of acid-related gastrointestinal diseases.
Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are among the most common chronic diseases in the world.
“Cutting edge” Treatments in the fight against asthma and other breathing disorders
The incidence of respiratory disease is increasing steadily. This is especially true in western industrialised nations where asthma and COPD are affecting more and more individuals each year. Recent estimates put the number of people suffering from asthma worldwide at 300 million.
Nycomed is currently developing new therapies designed to treat asthma and COPD and decrease the social and economic burden of these diseases. Nycomed’s focus is to understand the causes of the inflammation occurring in the lungs of affected patients and develop cutting edge therapies to reduce this process thereby providing disease control and improving the quality of life of our patients.